Web Release Date: July 27,
How Shall We Use the Proteomics Toolbox for Biomarker Discovery?
and
Department of Structural Biology and Bioinformatics, Faculty of Medicine & Pharmacy Section, Faculty of Sciences, Geneva University, Geneva, Switzerland, Laboratory Medicine Service, Department of Genetic & Laboratory Medicine, Geneva University Hospital, CH-1211 Geneva 14, Switzerland, CEA-DSV-iRTSV/BBSI, CEA Grenoble, 17 rue des martyrs, F-38054 Grenoble Cedex 9, France, and CNRS UMR 5092, 17 rue des martyrs, F-38054 Grenoble Cedex 9, France
Received April 12, 2007
Abstract:
Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce. In this perspective paper, we try to highlight and analyze the main causes for this limited success, and to suggest alternate strategies, which will avoid them, without eluding the foreseeable weak points of these strategies. Two major strategies are analyzed, namely, the switch from body fluids to cell and tissues for the initial biomarker discovery step or, if body fluids must be analyzed, the implementation of highly selective protein selection strategies.
Keywords: proteomics 
biomarkers plasma biological fluids cerebrospinal fluid
Download the full text: PDF | HTML
